{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T12:55:06Z","timestamp":1768913706754,"version":"3.49.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,10]]},"abstract":"<jats:p>With recent advances in treatment modalities, the survival time for patients with small cell lung cancer (SCLC) has increased, along with the likelihood of recurrence of a second primary tumor. However, patient treatment options and prognosis remain uncertain. This research evaluated the survival rates of patients with SCLC with a second malignancy, aiming to provide new insights and statistics on whether to proceed with more active therapy. SCLC patients were selected based on the Surveillance, Epidemiology, and End Results (SEER) database, updated on April 15, 2021. We defined those with SCLC followed by other cancers (1st of 2 or more primaries) in the sequence number as S-second primary malignant cancer (S-SPM). Those who had other cancers followed by SCLC (2nd of 2 or more primaries) were defined as OC-SCLC. We performed Kaplan\u2013Meier survival analysis, life table analysis, univariate analysis, stratified analysis, and multiple regression analysis of patient data. We considered the difference statistically meaningful at <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05. After selection, data for 88,448 participants from the SEER database was included in our analysis. The mean survival time for patients with S-SPM was 69.349 months (95% confidence interval [CI]: 65.939, 72.759), and the medium duration of survival was 34 months (95% CI: 29.900, 38.100). Univariate analysis showed that for overall survival, the hazard ratio (HR) of S-SPM was 0.367 (95% CI: 0.351, 0.383), which was 0.633 lower than that of patients with solitary SCLC and 0.606 lower than that of patients with OC-SCLC. For cancer-specific survival (CSS), the HR of S-SPM was 0.285 (95% CI: 0.271, 0.301), which was 0.715 lower than for patients with solitary SCLC and 0.608 lower than that for patients with OC-SCLC. Multiple regression analysis showed that the HR values of S-SPM were lower than those of patients with single SCLC and those with OC-SCLC, before and after adjustment for variables. Kaplan\u2013Meier survival curves showed that patients with S-SPM had significantly better survival times than the other groups. The survival time and prognosis of patients with S-SPM were clearly superior to those with single SCLC and OC-SCLC.<\/jats:p>","DOI":"10.1097\/md.0000000000032772","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T16:27:10Z","timestamp":1676046430000},"page":"e32772","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Better survival and prognosis in SCLC survivors after combined second primary malignancies: A SEER database-based study"],"prefix":"10.1097","volume":"102","author":[{"given":"Silin","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengfei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lang","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayue","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxiong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiping","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-3-319-40389-2_2","article-title":"Diagnosis and molecular classification of lung cancer.","volume":"170","author":"Rodriguez-Canales","year":"2016","journal-title":"Cancer Treat Res"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"8661","DOI":"10.3390\/ijms22168661","article-title":"Current and future development in lung cancer diagnosis.","volume":"22","author":"Nooreldeen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.mayocp.2019.01.034","article-title":"Current diagnosis and management of small-cell lung cancer.","volume":"94","author":"Wang","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"145","DOI":"10.21037\/atm.2018.03.31","article-title":"Advanced small cell lung cancer (SCLC): new challenges and new expectations.","volume":"6","author":"Tsoukalas","year":"2018","journal-title":"Ann Transl Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"e13122","DOI":"10.15252\/emmm.202013122","article-title":"Mechanisms of small cell lung cancer metastasis.","volume":"13","author":"Ko","year":"2021","journal-title":"EMBO Mol Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1055\/s-0036-1592116","article-title":"Small cell lung cancer.","volume":"37","author":"Kalemkerian","year":"2016","journal-title":"Semin Respir Crit Care Med"},{"key":"R7-20250504","first-page":"39","article-title":"Small cell lung cancer (SCLC): no treatment advances in recent years.","volume":"5","author":"Koinis","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"a038240","DOI":"10.1101\/cshperspect.a038240","article-title":"Advances in small-cell lung cancer (SCLC) translational research.","volume":"11","author":"Drapkin","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3389\/fonc.2019.01552","article-title":"Resection of early-stage second primary non-small cell lung cancer after small cell lung cancer: a population-based study.","volume":"9","author":"Zhang","year":"2019","journal-title":"Front Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"e644","DOI":"10.1634\/theoncologist.2019-0266","article-title":"Second primary malignancies in patients with colorectal cancer: a population-based analysis.","volume":"25","author":"Jia","year":"2020","journal-title":"Oncologist"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1186\/s12885-021-08766-9","article-title":"Risks and cancer associations of metachronous and synchronous multiple primary cancers: a 25-year retrospective study.","volume":"21","author":"Tanjak","year":"2021","journal-title":"BMC Cancer"},{"key":"R12-20250504","first-page":"1230","article-title":"Trends in the incidence and overall survival of multiple primary cancers in Turkey.","volume":"25","author":"Sert","year":"2020","journal-title":"J BUON"},{"key":"R13-20250504","first-page":"89","article-title":"The etiology of second primary neoplasms.","volume":"12","author":"Kaiser","year":"1998","journal-title":"In Vivo"},{"key":"R14-20250504","first-page":"289","article-title":"Multiple primary cancers as clues to environmental and heritable causes of cancer and mechanisms of carcinogenesis.","volume":"157","author":"Hemminki","year":"2004","journal-title":"IARC Sci Publ"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/ijc.28988","article-title":"Multiple primary cancers as a guide to heritability.","volume":"135","author":"Cybulski","year":"2014","journal-title":"Int J Cancer"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"718644","DOI":"10.3389\/fonc.2021.718644","article-title":"N6-Methyladenosine Writer Gene ZC3H13 predicts immune phenotype and therapeutic opportunities in kidney renal clear cell carcinoma.","volume":"11","author":"Guo","year":"2021","journal-title":"Front Oncol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/jcmm.16227","article-title":"Predictive value of protease-activated receptor-2 (PAR(2)) in cervical cancer metastasis.","volume":"25","author":"He","year":"2021","journal-title":"J Cell Mol Med"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1159\/000227382","article-title":"Multiple primary neoplasms in patients with testicular germ cell tumor.","volume":"51","author":"Dieckmann","year":"1994","journal-title":"Oncology (Huntingt)"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1349-7006.2007.00657.x","article-title":"Incidence of multiple primary cancers in Nagasaki atomic bomb survivors: association with radiation exposure.","volume":"99","author":"Nakashima","year":"2008","journal-title":"Cancer Sci"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1038\/s41598-021-82248-7","article-title":"Second primary malignancies in colorectal cancer patients.","volume":"11","author":"Halamkova","year":"2021","journal-title":"Sci Rep"},{"key":"R21-20250504","first-page":"629384","article-title":"Multiple primary tumors over a lifetime.","volume":"33","author":"Copur","year":"2019","journal-title":"Oncology (Williston Park)"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/978-1-59745-416-2_5","article-title":"Epidemiology of multiple primary cancers.","volume":"471","author":"Soerjomataram","year":"2009","journal-title":"Methods Mol Biol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"e623","DOI":"10.1111\/jdv.16500","article-title":"Second primary melanoma: incidence rate and risk factors.","volume":"34","author":"Villani","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000381716","article-title":"Incidence of second primary malignancies in patients with neuroendocrine tumours.","volume":"102","author":"Clift","year":"2015","journal-title":"Neuroendocrinology"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.bjoms.2019.09.018","article-title":"Incidence, timing, presentation, treatment, and outcomes of second primary head and neck squamous cell carcinoma after oral cancer.","volume":"57","author":"Rogers","year":"2019","journal-title":"Br J Oral Maxillofac Surg"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1590\/S1808-86942010000200017","article-title":"Second primary tumor in patients with upper aerodigestive tract cancer.","volume":"76","author":"Priante","year":"2010","journal-title":"Braz J Otorhinolaryngol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s00405-015-3699-1","article-title":"Prognostic impact of second primary tumors in head and neck cancer.","volume":"273","author":"Patrucco","year":"2016","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"R28-20250504","first-page":"1152","article-title":"Second primary tumors involving non-small cell lung cancer: prevalence and its influence on survival.","volume":"127","author":"Duchateau","year":"2005","journal-title":"Chest"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1158\/0008-5472.CAN-20-2808","article-title":"Evasion of innate immunity contributes to small cell lung cancer progression and metastasis.","volume":"81","author":"Zhu","year":"2021","journal-title":"Cancer Res"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1200\/JCO.1992.10.10.1519","article-title":"The incidence of second primary tumors in long-term survivors of small-cell lung cancer.","volume":"10","author":"Heyne","year":"1992","journal-title":"J Clin Oncol"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ejcts.2008.08.004","article-title":"Multiple independent primary cancers do not adversely affect survival of the lung cancer patient.","volume":"34","author":"Aguil\u00f3","year":"2008","journal-title":"Eur J Cardiothorac Surg"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:01:46Z","timestamp":1746327706000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032772","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,10]]}}}